This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Friday's Health Winners & Losers

Health stocks were upbeat on Friday amid little news and ahead of next week's earnings kickoff.

Pharma companies Merck (MRK - Get Report) and Schering-Plough (SGP), recently in the spotlight for negative news surrounding cholesterol drugs Zetia and Vytorin, enjoyed some investor positivism on Friday. A day after announcing its cost-cutting response to the drug turmoil, Schering shares added 71 cents, or 4.6%, to $16.09. Merck shares rose $1.60, or 4.2%, to $39.96.

Among medical-device stocks: Boston Scientific's (BSX) shares added 4% to $14.07, St. Jude Medical (STJ) tacked on 2.8% to $45.29, and Medtronic (MDT) gained 1.3% to $49.64.

Meanwhile, biotech stocks Celgene (CELG - Get Report), Cephalon (CEPH) and Biogen Idec (BIIB - Get Report) all gained more than 1.5% on Friday, helping boost the Nasdaq and Amex biotechnology indices to grow 1.2% and 1.8%, respectively.

Lazard analyst Matthew Osborne said in a note to investors Friday that he expects biotech Genzyme (GENZ) to deliver earnings growth of 17% in the next three years. Osborne, who has a buy rating and a $90 price target for Genzyme, is also optimistic about midstage data on Genzyme's Clolar for pediatric leukemia and also its candidate for Gaucher disease, due out midyear. Genzyme shares added $1.36, or 1.8%, to $75.94.

Elsewhere, Draxis Health (DRAX) said Friday that it will be acquired by Indian drug company Jubilant Organosys for $255 million, or $6 a share. The price is a 22.5% premium over Draxis' price at market close on Thursday. The transaction is expected to close in the second quarter. Shares of the Canadian based company rose $1, or 20.4%, to $5.90 on Friday.

Also, Indevus Pharmaceuticals (IDEV) said Thursday post close that it licensed its prostate cancer implant Vantas to Orion Corp. for a potential price of $21 million. Indevus will receive $7 million upfront and up to $14 million more tied to approvals and sales milestones. Its shares rose 8 cents, or 1.7%, to $4.69 on Friday.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BIIB $289.15 0.00%
CELG $112.67 0.00%
MRK $53.48 0.00%
AAPL $118.88 0.00%
FB $105.74 0.00%


Chart of I:DJI
DOW 17,812.19 +19.51 0.11%
S&P 500 2,089.14 +2.55 0.12%
NASDAQ 5,102.8080 +0.33 0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs